Circulating versus cellular tumor DNA for the detection of BTK resistant CLL clones

Resistance mutations can be detected in 75% of CLL patients progressing under BTK inhibitor therapy. Using semiquantitative wild-type-blocking (WTB) RT-PCR for BTK and Sanger sequencing for PLCG2 mutations, we compared detection sensitivity of cellular versus circulating tumor DNA (ctDNA) in 20 samp...

Descripción completa

Detalles Bibliográficos
Autores principales: Trummer, Arne, Schier, Wiebke, Krauter, Jürgen, Hannig, Horst, Christmann, Jens
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9706612/
https://www.ncbi.nlm.nih.gov/pubmed/36457814
http://dx.doi.org/10.1016/j.lrr.2022.100359

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9706612/
https://www.ncbi.nlm.nih.gov/pubmed/36457814
http://dx.doi.org/10.1016/j.lrr.2022.100359

Ejemplares similares